BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics
BTAI Price/Volume Stats
Current price | $2.55 | 52-week high | $61.12 |
Prev. close | $2.98 | 52-week low | $2.51 |
Day low | $2.51 | Volume | 230,200 |
Day high | $2.93 | Avg. volume | 214,195 |
50-day MA | $5.82 | Dividend yield | N/A |
200-day MA | $14.34 | Market Cap | 7.91M |
BTAI Stock Price Chart Interactive Chart >
BioXcel Therapeutics, Inc. (BTAI) Company Bio
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
BTAI Price Returns
1-mo | -58.47% |
3-mo | -69.37% |
6-mo | -76.33% |
1-year | -93.52% |
3-year | -99.10% |
5-year | -99.57% |
YTD | -57.37% |
2024 | -87.33% |
2023 | -86.27% |
2022 | 5.66% |
2021 | -56.00% |
2020 | 216.22% |
Loading social stream, please wait...